Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 7/2018

Open Access 01-07-2018 | Original paper

Increasing preoperative body size in breast cancer patients between 2002 and 2016: implications for prognosis

Authors: Agatha Wisse, Helga Tryggvadottir, Maria Simonsson, Karolin Isaksson, Carsten Rose, Christian Ingvar, Helena Jernström

Published in: Cancer Causes & Control | Issue 7/2018

Login to get access

Abstract

Overweight and obesity are increasing worldwide, but the extent in breast cancer patients is unknown. The two aims were to study secular trends in preoperative body mass index (BMI), waist circumference, and breast volume and their impacts on clinical outcome. BMI, waist circumference, and breast volume were measured preoperatively in 24–99-year-old primary breast cancer patients (n = 640) in Sweden 2002–2016. The measurements were analyzed alone and combined in relation to recurrence and overall survival (OS). BMI, waist circumference, and breast volume increased 2002–2016 (ptrends < 0.0001). Of these, a breast volume ≥ 850 mL was associated with the strongest recurrence-risk (adjusted hazard ratio [adjHR] 1.67; 95% CI 1.17–2.39), especially combined with waist circumference ≥ 80 cm (adjHR 2.07; 95% CI 1.25–3.44), while BMI ≥ 25 kg/m2 or large waist circumference conferred almost a twofold risk for death (both Log-Rank p ≤ 0.0001). Chemotherapy seemed to counteract the negative impact of a high BMI or large waist circumference on OS. Large breast volume was the strongest predictor for recurrence in all treatment groups. In conclusion, preoperative BMI, waist circumference, and breast volume increased between 2002 and 2016. Larger body size negatively impacted breast cancer-free interval and OS. If confirmed, body measurements may help select patients requiring more individualized treatment.
Appendix
Available only for authorised users
Literature
1.
2.
Arnold M, Leitzmann M, Freisling H et al (2016) Obesity and cancer: an update of the global impact. Cancer Epidemiol 41:8–15CrossRefPubMed
3.
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386CrossRefPubMed
4.
Magnusson C, Baron J, Persson I et al (1998) Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer 76:29–34CrossRefPubMed
5.
Phipps AI, Li CI (2010) Breast cancer biology and clinical characteristics. Breast cancer epidemiology. Springer, New York
6.
Brenner DR, Brockton NT, Kotsopoulos J et al (2016) Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer Causes Control 27:459–472CrossRefPubMedPubMedCentral
7.
Engin A (2017) Obesity-associated breast cancer: analysis of risk factors. Adv Exp Med Biol 960:571–606CrossRefPubMed
8.
Jernström H, Barrett-Connor E (1999) Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J Womens Health Gend Based Med 8:1265–1272CrossRefPubMed
9.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638CrossRefPubMed
10.
Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B (2008) Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 111:329–342CrossRefPubMed
11.
Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123:627–635CrossRefPubMed
12.
Sinicrope FA, Dannenberg AJ (2011) Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol 29:4–7CrossRefPubMed
13.
Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA (2005) Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 14:2009–2014CrossRefPubMed
14.
15.
Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM (2017) Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin 67(5):378–397CrossRefPubMedPubMedCentral
16.
Ambrosone CB, Hong CC, Goodwin PJ. (2015) Host factors and risk of breast cancer recurrence: genetic, epigenetic and biologic factors and breast cancer outcomes. Adv Exp Med Biol 862:143–153CrossRefPubMed
17.
Ewertz M, Jensen MB, Gunnarsdottir KA et al (2011) Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 29:25–31CrossRefPubMed
18.
Chan DS, Norat T (2015) Obesity and breast cancer: not only a risk factor of the disease. Curr Treat Options Oncol 16:22CrossRefPubMed
19.
George SM, Bernstein L, Smith AW et al (2014) Central adiposity after breast cancer diagnosis is related to mortality in the Health, Eating, Activity, and Lifestyle study. Breast Cancer Res Treat 146:647–655CrossRefPubMed
20.
Markkula A, Bromée A, Henningson M et al (2012) Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort. Cancer Causes Control 23:1307–1316CrossRefPubMed
21.
22.
Ferlay J, Héry C, Autier P, Sankaranarayanan R (2010) Global burden of breast cancer. In: Li C (ed) Breast cancer epidemiology. Springer, New York
23.
24.
25.
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M (1993) Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction 88:791–804CrossRefPubMed
26.
Simonsson M, Markkula A, Bendahl PO, Rose C, Ingvar C, Jernstrom H (2014) Pre- and postoperative alcohol consumption in breast cancer patients: impact on early events. SpringerPlus 3:261CrossRefPubMedPubMedCentral
27.
Dupont WD, Plummer WD. (1990) Power and sample size calculations: a review and computer program. Control Clin Trials 11:116–128CrossRefPubMed
28.
Pouliot MC, Despres JP, Lemieux S et al (1994) Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 73:460–468CrossRefPubMed
29.
Niraula S, Ocana A, Ennis M, Goodwin PJ. (2012) Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 134:769–781CrossRefPubMed
30.
Endogenous Hormones Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, Roddam AW. (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11:530–542CrossRef
31.
Rice MS, Tworoger SS, Rosner BA, Pollak MN, Hankinson SE, Tamimi RM. (2012) Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses’ Health Studies. Breast Cancer Res Treat 136:805–812CrossRefPubMedPubMedCentral
32.
Voudouri K, Berdiaki A, Tzardi M, Tzanakakis GN, Nikitovic D (2015) Insulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant disease. Anal Cell Pathol 2015:975495CrossRef
33.
Vona-Davis L, Rose DP (2013) The obesity-inflammation-eicosanoid axis in breast cancer. J Mammary Gland Biol Neoplasia 18:291–307CrossRefPubMed
34.
Nicolini A, Carpi A, Rossi G (2006) Cytokines in breast cancer. Cytokine Growth Factor Rev 17:325–337CrossRefPubMed
35.
Pfeiler G, Konigsberg R, Fesl C et al (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 29:2653–2659CrossRefPubMed
36.
Pfeiler G, Stoger H, Dubsky P et al (2013) Efficacy of tamoxifen +/− aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. Br J Cancer 108:1408–1414CrossRefPubMedPubMedCentral
37.
Ewertz M, Gray KP, Regan MM et al (2012) Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 30:3967–3975CrossRefPubMedPubMedCentral
38.
Dowsett M, Cuzick J, Ingle J et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509–518CrossRefPubMed
39.
Early Breast Cancer Trialists’ Collaborative Group, Peto R, Davies C et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444CrossRef
40.
Early Breast Cancer Trialists’ Collaborators Group, McGale P, Taylor C et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383:2127–2135CrossRef
41.
42.
Griggs JJ, Mangu PB, Anderson H et al (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 30:1553–1561CrossRefPubMed
43.
44.
Persson M, Simonsson M, Markkula A, Rose C, Ingvar C, Jernström H. (2016) Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort. Br J Cancer 115:382–390CrossRefPubMedPubMedCentral
45.
Sheean PM, Hoskins K, Stolley M (2012) Body composition changes in females treated for breast cancer: a review of the evidence. Breast Cancer Res Treat 135:663–680CrossRefPubMedPubMedCentral
Metadata
Title
Increasing preoperative body size in breast cancer patients between 2002 and 2016: implications for prognosis
Authors
Agatha Wisse
Helga Tryggvadottir
Maria Simonsson
Karolin Isaksson
Carsten Rose
Christian Ingvar
Helena Jernström
Publication date
01-07-2018
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 7/2018
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-018-1042-z

Other articles of this Issue 7/2018

Cancer Causes & Control 7/2018 Go to the issue

Original paper

Racial differences in the relationship between tobacco, alcohol, and the risk of head and neck cancer: pooled analysis of US studies in the INHANCE Consortium

Original paper

The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study

Letter to the editor

Re: Kheifets et al. (2017): Residential magnetic fields exposure and childhood leukemia: a population-based case–control study in California

Original paper

Associations of dietary fat with risk of early neoplasia in the proximal colon in a population-based case–control study

Original paper

A pilot study of prostate cancer knowledge among African American men and their health care advocates: implications for screening decisions

Original paper

Black/white differences in treatment and survival among women with stage IIIB–IV breast cancer at diagnosis: a US population-based study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits